These results suggest that the immune phenotype of LGG and GBM might differ, probably due to the immunosuppressive role of the metabolite 2-hydroxyglutarate (2-HG) in isocitrate dehydrogenase (IDH)-mutated tumors [13, 14]. The gene discussed is IDH1; the disease is glioblastoma.